Effects of Exenatide on Hypothalamic Obesity

NCT01061775 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide could help reduce body mass index (BMI) in people with hypothalamic obesity.

Status Completed The study has finished.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 19 people

Who can join Ages 10–21 · all sexes

Timeline Started 2010-01 · est. completion 2019-03

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT01061775 ↗

Description as written by the study sponsor.

The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.

Treatments tested

Exenatide also known as Byetta Drug

5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.

Main thing measured	BMI Change
Sponsor	Children's Hospitals and Clinics of Minnesota
Conditions studied	Hypothalamic Obesity
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01061775 ↗